Clinical trials: Cancer of the Liver
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…
- Trial name
- NCT06492395
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Carcinoma, Hepatocellular
Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)
In patients with unresectable/advanced Hepatocellular Carcinoma receiving Capecitabin, we anticipate that the proposed chemotherapy will have a delay in progression of the disease .
- Trial name
- HCC-CAP (NCT00464295)
- Testing
- Capecitabine in HCC
- Where
- Pakistan
- Volunteers
- 15 people
- Sponsor
- Aga Khan University
Hepatocellular Carcinoma
Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells
To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.
- Trial name
- NCT04032392
- Testing
- autologous γδT cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma
18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the fourth leading cause of cancer-related death worldwide.
- Trial name
- NCT05871892
- Testing
- 18F-FDGal PET/CT or PET/MRI
- Where
- Denmark
- Volunteers
- 125 people
- Sponsor
- University of Aarhus
Advanced Hepatocellular Carcinoma
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
- Trial name
- NCT05628545
- Testing
- GDKM-100 injection
- Where
- China
- Sponsor
- Guangdong GD Kongming Biotech LLC
Liver Diseases, Liver Transplant; Complications
Design and Implementation of the Pediatric Liver Transplantation Biobank
The purpose of the pediatric liver transplant biobank is to systematically collect clinical specimens from pediatric end-stage liver disease.
- Conditions
- Liver Diseases, Liver Transplant; Complications, Pediatric ALL
- Trial name
- NCT04477967
- Testing
- No intervention
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, HCC
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis.
- Trial name
- NCT04455932
- Testing
- Abbreviated non-contrast MRI of the liver, Ultrasound surveillance, Multiphase contrast-enhanced liver MRI
- Where
- 10 sites in Australia, New Zealand
- Volunteers
- 476 people
- Sponsor
- Concord Repatriation General Hospital
HCC - Hepatocellular Carcinoma
Sarcopenia and Systemic Therapy in HCC
This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.
- Trial name
- Sarco HCC (NCT06805552)
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Liver Cancer, Hepatocellular Carcinoma (HCC)
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
This is a research study to evaluate change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30), from baseline to 1 month post…
- Trial name
- NCT04933435
- Testing
- Quality of life questionnaires
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Duke University
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatment.
- Trial name
- NCT01423734
- Testing
- magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Carcinoma, Hepatocellular
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
This multicenter, open-label study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicities of onartuzumab as single agent or in combination with sorafenib in participants with advanced hepatocellular…
- Trial name
- NCT01897038
- Testing
- Onartuzumab, Sorafenib
- Where
- 10 sites in United States, Hong Kong and 2 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Liver Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00093548
- Testing
- alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
- Sponsor
- Jonsson Comprehensive Cancer Center
HCC - Hepatocellular Carcinoma
QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.
- Trial name
- QL1706 (NCT06822985)
- Testing
- QL1706
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Wan-Guang Zhang
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there is no effective systemic chemotherapy for HCC.
- Trial name
- SECOX (NCT00752063)
- Testing
- Sorafenib with Capecitabine and Oxaliplatin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.